Clinical Evaluation of the Infinity Deep Brain Stimulation System (PROGRESS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02989610 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 12, 2016
Results First Posted : November 19, 2020
Last Update Posted : October 8, 2021
|
Sponsor:
Abbott Medical Devices
Information provided by (Responsible Party):
Abbott Medical Devices
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this post-market study is to characterize the clinical performance of the Infinity Deep Brain Stimulation (DBS) system, including the Implantable Pulse Generator (IPG), directional DBS leads, extensions, iPad clinician programmer, iPod patient controller and related system components.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson Disease | Device: Omnidirectional stimulation Device: Directional stimulation | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 234 participants |
| Allocation: | N/A |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | Single-arm crossover study, with double-blind, randomized sequence of testing for primary endpoint. Although this was a crossover study, the primary endpoint was a double-blind randomized controlled assessment of therapeutic window during the 3-month clinic visit. Subjects received both directional and omnidirectional stimulation, and the order was randomized. |
| Masking: | None (Open Label) |
| Masking Description: | Single-arm, open-label design for overall study. Primary endpoint is based on double-blind, randomized testing of omnidirectional and directional DBS during three-month follow visit. Participants are blinded to all details of stimulation for first six months, including details of stimulation testing. Outcomes assessor is blinded to stimulation type for primary and secondary endpoints. |
| Primary Purpose: | Treatment |
| Official Title: | Post Market Clinical Follow Up Evaluating the Infinity Deep Brain Stimulation Implantable Pulse Generator System |
| Actual Study Start Date : | January 31, 2017 |
| Actual Primary Completion Date : | August 7, 2019 |
| Estimated Study Completion Date : | March 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Parkinson disease
MedlinePlus related topics:
Parkinson's Disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Omnidirectional followed by directional DBS
Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary endpoint is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.
|
Device: Omnidirectional stimulation
At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated at the best level for omnidirectional stimulation with the Infinity DBS lead. Device: Directional stimulation At the 3-month follow-up, therapeutic window, symptom relief and side effect thresholds are evaluated using directional contacts at the best segmented level of the Infinity DBS lead. |
Primary Outcome Measures :
- Percentage of Participants With Wider Therapeutic Window With Directional Programming (Superiority) [ Time Frame: 3-month follow-up visit after initial programming ]Therapeutic window is the range of stimulation amplitude that produces symptom relief without causing side effects. Proportion of subjects with a wider therapeutic window using directional stimulation, compared to a threshold of 60%. Based on randomized, double-blind evaluation using within-subject control.
Secondary Outcome Measures :
- Percentage of Participants With Wider Therapeutic Window With Directional Programming (Non-inferiority) [ Time Frame: 3-month follow-up visit after initial programming ]Therapeutic window is the range of stimulation amplitude that produces symptom relief without causing side effects. The proportion of subjects with wider therapeutic window using directional stimulation will be compared to a performance goal of 60% with a non-inferiority threshold of 40%. Based on randomized, double-blind evaluation using within-subject control.
- Change in UPDRS III Score on and Off Stimulation (Medication on) at 3 and 6 Months [ Time Frame: 3-month and 6-month follow-up visits ]Change with stimulation on vs. off in Unified Parkinson's Disease Rating Scale (UPDRS) part III motor examination at 3 months using omnidirectional stimulation, compared to 6 months using directional stimulation. UPDRS part III contains 27 questions used to measures severity of Parkinson's motor symptoms. The range of scores is 0 to 108, with higher score indicating greater symptoms. Subjects are on medication for the assessment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subject is able to provide informed consent;
- Subject is diagnosed with Parkinson's disease (PD) and has been recommended to receive an Infinity DBS system with a bilateral DBS implant in the Subthalamic Nucleus (STN), or has received an implant of an Infinity system with bilateral lead implants in the STN;
- Subject must be available for follow-up visits.
Exclusion Criteria:
- Subject is not a surgical candidate;
- In the investigator's opinion, the subject is unable to tolerate multiple programming sessions within a single setting;
- Subject is unable to comply with the follow-up schedule.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02989610
Locations
Show 49 study locations
Sponsors and Collaborators
Abbott Medical Devices
Investigators
| Principal Investigator: | Alfons Schnitzler, MD | Heinrich-Heine-Universität Düsseldorf, Institute for Clinical Neuroscience | |
| Principal Investigator: | Jan Vesper, MD | Heinrich-Heine-Universität Düsseldorf, Department of Functional and Stereotactic Neurosurgery |
Study Documents (Full-Text)
Documents provided by Abbott Medical Devices:
Documents provided by Abbott Medical Devices:
Study Protocol and Statistical Analysis Plan [PDF] November 23, 2019
| Responsible Party: | Abbott Medical Devices |
| ClinicalTrials.gov Identifier: | NCT02989610 |
| Other Study ID Numbers: |
SJM-CIP-10061 |
| First Posted: | December 12, 2016 Key Record Dates |
| Results First Posted: | November 19, 2020 |
| Last Update Posted: | October 8, 2021 |
| Last Verified: | October 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Product Manufactured in and Exported from the U.S.: | Yes |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases |